As the demographic of cannabis users in the United States expands to include a growing number of older Americans, experts at Stanford Medicine are issuing a critical alert: today’s marijuana products are significantly more potent than many realize, carrying a spectrum of potential health risks that warrant careful consideration and open communication with healthcare providers. This evolving landscape necessitates a deeper understanding of the drug’s current form and its implications for an aging population.
A Shifting Landscape of Cannabis Use
The increase in cannabis consumption among older adults is not a sudden phenomenon but rather a gradual shift influenced by several converging factors. The widespread legalization of medical cannabis, beginning with California in 1996 and spreading to 40 states and the District of Columbia, has significantly improved accessibility. Simultaneously, recreational legalization in 24 states and D.C. has further destigmatized its use and normalized its presence in society. This broader acceptance, coupled with an aging population actively seeking alternatives for chronic conditions, has created a fertile ground for increased usage among those over 65.
Eloise Theisen, a geriatric nurse practitioner specializing in cannabis therapy at Stanford Medicine, witnessed this trend firsthand. Her own experience with chronic pain following a severe car accident, where traditional treatments proved insufficient, led her to explore cannabis. Upon returning to work in an oncology clinic, she observed a significant number of patients already using or considering cannabis, often without the benefit of professional medical guidance. "I found that our patients were going to use it whether their providers approved of it or not," Theisen stated. "Many of our patients were older, and they had risks that needed to be evaluated and addressed before they started using cannabis." This realization highlighted a critical gap in patient care and informed her specialized focus.
The Unprecedented Potency of Contemporary Cannabis
A core concern voiced by Stanford experts is the dramatic increase in the potency of cannabis products compared to what many older adults may have encountered in their younger years. In the 1970s, the average tetrahydrocannabinol (THC) content, the primary psychoactive compound in marijuana, ranged from a modest 1% to 4%. Today, legal cannabis flower typically contains around 20% THC, with some strains reaching as high as 35%. This represents a more than tenfold increase in psychoactive potency.
The potency escalation doesn’t stop with dried flower. Concentrated forms like oils and edibles can contain THC levels approaching 90%. Furthermore, synthetic marijuana products, such as "spice" or "K2" – though illegal in many jurisdictions, including California – can be even more potent and have been linked to severe adverse health events. Dr. Claudia Padula, an assistant professor of psychiatry and behavioral sciences at Stanford Medicine, emphasized the scientific challenge this presents: "We’re trying to catch up in our understanding of how that drastic of an increase in the psychoactive ingredient is impacting the brain and the body."
This surge in potency has tangible consequences. A Canadian study examining emergency room visits before and after nationwide cannabis legalization revealed a nearly threefold increase in cannabis poisoning cases among adults over 65. Dr. Smita Das, a clinical associate professor of psychiatry and behavioral sciences at Stanford Medicine, underscored this point: "There are so many different formulations and so many different strengths. This is really not the cannabis of the ’70s." The risk of accidental overuse, leading to adverse reactions such as anxiety, paranoia, rapid heart rate, and confusion, is therefore substantially higher.
Cardiovascular Risks and Cognitive Concerns for Older Adults
One of the most significant areas of concern for older adults is the potential link between regular cannabis use and cardiovascular disease. Heart disease remains the leading cause of death in the United States, and any factor that could exacerbate this risk warrants serious attention. Dr. Joseph Wu, director of the Stanford Cardiovascular Institute, highlighted research indicating that THC can trigger inflammation in blood vessels, as observed in animal studies. Epidemiological research has also suggested associations between cannabis use and increased risks of heart attacks and strokes in humans.
While the exact mechanisms are still under investigation and research is ongoing, some studies have linked regular cannabis use to a notable increase in the incidence of heart attacks and strokes. Dr. Wu cautioned that while these risks may be lower than those associated with heavy tobacco or alcohol use, many cannabis users also engage in these other behaviors. The synergistic effect of combining these substances could amplify cardiovascular dangers. Furthermore, smoking cannabis, much like smoking tobacco, has been associated with an increased risk of lung cancer and cancers of the head and neck. Dr. Wu’s team suggests that smoking and vaping cannabis may promote more inflammation than edible products, although he stressed that "there is no safe amount of cannabis. Low doses and occasional use are still associated with vascular inflammation. Abstinence is the safest option for heart health."
Beyond cardiovascular issues, older adults are also susceptible to cognitive and neurological complications. Theisen noted that patients may experience dizziness, confusion, falls, and a worsening of existing cognitive conditions like dementia. A key factor contributing to these risks is the slower metabolism of cannabis in older individuals. This means the drug can remain in the body for longer periods, potentially prolonging its effects and increasing the likelihood of adverse interactions with prescription medications.
The interaction between cannabis compounds, particularly cannabidiol (CBD), and pharmaceuticals is a growing concern. CBD can interfere with the enzymes responsible for metabolizing certain medications, such as blood thinners. This interference can lead to elevated drug levels in the body, increasing the risk of bleeding, especially after an injury or fall. In some instances, cannabis use might also diminish the effectiveness of vital medications.
The Reality of Cannabis Addiction in Seniors
A prevalent misconception is that cannabis is not addictive. However, Dr. Das counters this, citing research that suggests otherwise. Studies indicate that approximately 30% of regular cannabis users may develop cannabis use disorder, a condition characterized by the drug’s significant impact on an individual’s daily life, including withdrawal symptoms, increased tolerance, and interference with personal relationships and responsibilities.
The lower addiction rates compared to alcohol or opioids do not negate the risk, especially for older adults who may not typically be perceived as being at risk for substance use disorders. Dr. Das observes that "older adults may not necessarily be disclosing cannabis use to their providers unless specifically asked. This isn’t a population we traditionally think about in terms of using cannabis." This lack of routine inquiry can mean that healthcare providers are unaware of a patient’s cannabis use, potentially missing opportunities to address associated risks or provide support. Dr. Das advocates for a more open dialogue, stating, "If someone comes to me for another reason such as depression or alcohol use disorder, I might be the first person who has asked them about their cannabis use." For those seeking to reduce or cease their use, consulting with a doctor or addiction specialist is crucial, with therapies like cognitive behavioral therapy proving effective.
Limited Evidence for Widespread Medical Benefits
While many older adults turn to cannabis for relief from chronic pain, insomnia, or anxiety, experts emphasize that there is no broad medical consensus on its efficacy for these conditions. The Food and Drug Administration (FDA) has not approved cannabis itself for medical treatment. However, two cannabis-derived compounds have received FDA approval: CBD for specific forms of childhood epilepsy and dronabinol (a synthetic cannabinoid) for nausea and appetite loss in patients undergoing cancer chemotherapy or those with HIV/AIDS. Additionally, some countries approve cannabis for managing muscle spasms associated with multiple sclerosis, though the U.S. has not followed suit.
The marketing of CBD products for a wide array of ailments, including pain, sleep disturbances, anxiety, and substance use disorders, often outpaces the scientific evidence. Research on cannabis for chronic pain has yielded mixed results, with some studies reporting pain relief while others highlight significant placebo effects. The American Psychiatric Association, with input from experts like Dr. Das, has issued statements opposing cannabis as a psychiatric treatment due to a lack of robust evidence demonstrating its effectiveness for psychiatric disorders.
Conversely, Theisen points to the palliative care setting, where patients facing life-limiting illnesses often seek alternatives to opioid medications for symptom management. She notes that cannabis can help alleviate cancer-related symptoms, and some research suggests it may enable patients to reduce their opioid intake. Furthermore, she highlights the potential for cannabis to provide a sense of well-being and joy. "THC has gotten a bad rap over the years, but in very small doses it can be therapeutic," she explains. "There’s also a lot of stigma around its effects of euphoria. In our patients who may have months to a few years to live, still being able to experience joy is really important." This perspective underscores the nuanced role cannabis can play for certain patient populations, albeit with careful consideration.
The Imperative of Honest Conversations with Healthcare Providers
Despite differing views on the precise medical utility of cannabis, Stanford experts universally agree on one critical point: open and honest communication between older adults and their healthcare providers is paramount before initiating cannabis use. Theisen strongly advocates for patients to consult with medical professionals rather than relying on advice from dispensary staff or self-experimentation. She recounts instances from the early days of legalization where patients inadvertently consumed excessively high doses of edibles due to inadequate guidance, leading to negative experiences and a reluctance to try cannabis again.
Navigating the complex world of cannabis information can be challenging. Healthcare providers are uniquely positioned to help patients assess the appropriateness of cannabis use, explore alternative treatments, and identify potential risks associated with their existing medical conditions and current medications. "Your primary care physician will know the constellation of your medical conditions and other medications you might be on," Dr. Padula advises. "Talking to your doctor and letting them know not only what you’re prescribed, but what you’re using recreationally, will help formulate a way to do it in as safe a manner as possible." This collaborative approach ensures that decisions about cannabis use are informed, personalized, and prioritize the overall health and safety of older adults.
